(Q53152113)

11 May 2018

title

Activity of azacitidine in chronic myelomonocytic leukemia. (English)

1 reference

11 May 2018

1 reference

Rubens Costa

1

1 reference

11 May 2018

Haifaa Abdulhaq

2

1 reference

11 May 2018

Bushra Haq

3

1 reference

11 May 2018

Richard K Shadduck

4

1 reference

11 May 2018

Joan Latsko

5

1 reference

11 May 2018

Mazen Zenati

6

1 reference

11 May 2018

Folefac D Atem

7

1 reference

11 May 2018

James M Rossetti

8

1 reference

11 May 2018

Entezam A Sahovic

9

1 reference

11 May 2018

John Lister

10

1 reference

11 May 2018

language of work or name

English

0 references

publication date

23 December 2010

1 reference

11 May 2018

published in

Cancer

1 reference

11 May 2018

volume

117

1 reference

11 May 2018

issue

12

1 reference

11 May 2018

page(s)

2690-2696

1 reference

11 May 2018

Proposals for the classification of the myelodysplastic syndromes

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Risk assessment in chronic myelomonocytic leukemia (CMML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Outcome of allo-SCT for chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25759

7 January 2021

Identifiers

DOI

10.1002/CNCR.25759

1 reference

11 May 2018

PubMed ID

21656746

1 reference

11 May 2018